Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment
Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
1. A method of reducing blood glucose in a mammal, comprising:
administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to the mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol); vitamin D3 (cholecalciferol); vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D 3 (calcitriol), or a combination thereof, and
administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
thereby reducing blood glucose in the mammal.
2. A method of treating type 2 diabetes in a mammal, comprising:
administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to the mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol); vitamin D3 (cholecalciferol): vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D 3 (calcitriol), or a combination thereof, and
administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
thereby treating type 2 diabetes in the mammal.
3. A method, comprising:
administering a therapeutically effective amount of one or more vitamin D receptor (VDR) agonists to a mammal, wherein the one or more VDR agonists is calcipotriol, 25-hydroxy-D 3 (25-OH-D 3 ) (calcidiol); vitamin D3 (cholecalciferol); vitamin D2 (ergocalciferol), 1α,25-dihydroxyvitamin D 3 (calcitriol), or a combination thereof, and
administering a therapeutically effective amount of one or more bromodomain-containing protein 9 (BRD9) antagonists to the mammal, wherein the one or more BRD9) antagonists is I-BRD-9, TP742, BI-7273, BI-9564, dBRD9, GNE-375, LP-99, or a combination thereof,
wherein the method reduces fed and fasting blood glucose, increases insulin sensitivity, increases glucose tolerance, increases insulin secretion, increases beta cell function, increases the size of islets, reduced beta cell death, increases insulin granules, or combinations thereof, in the mammal.
4. The method of claim 1 , wherein the therapeutically effective amount of the one or more VDR agonists is at least 0.01 mg/kg, the therapeutically effective amount of the one or more BRD9 antagonists is at least 0.1 mg/kg, or both.
5. The method of claim 1 , wherein the administering is subcutaneous, intraperitoneal, intramuscular, intravenous or intrathecal.
6. The method of claim 1 , wherein the mammal is a cat or dog.
7. The method of claim 1 , wherein the mammal is a human.
8. The method of claim 2 , wherein the VDR agonist is calcipotriol and the BRD9 antagonist is I-BRD9.
9. The method of claim 3 , wherein the VDR agonist is calcipotriol and the BRD9 antagonist is I-BRD-9.
10. The method of claim 2 , wherein the method further comprises administering an additional therapeutic compound.
11. The method of claim 1 , wherein the VDR agonist is calcipotriol and the BRD9 antagonists is I-BRD9.
12. The method of claim 1 , wherein the one or more VDR agonists and one or more BRD9 antagonists are administered concurrently.
13. The method of claim 1 , wherein the one or more VDR agonists and one or more BRD9 antagonists are administered sequentially.
14. The method of claim 1 , wherein the one or more VDR agonists, one or more BRD9 antagonists, or both, are part of a nanoparticle.
15. The method of claim 1 , wherein the method further comprises administering an additional therapeutic compound.
16. The method of claim 15 , wherein the additional therapeutic compound is insulin, an alpha-glucosidase inhibitor, amylin agonist, dipeptidyl-peptidase 4 (DPP-4) inhibitor, meglitinide, sulfonylurea, or a peroxisome proliferator-activated receptor (PPAR)-gamma agonist.
17. The method of claim 16 , wherein the PPAR-gamma agonist is a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar.
18. The method of claim 17 , wherein the TZD is pioglitazone, rosiglitazone, rivoglitazone, or troglitazone.